GlobeNewswire

Align Technology Reaches One Millionth Invisalign(R) Patient in the EMEA Region

Dela

Milestone Reflects Accelerating Adoption of Invisalign Treatment Among Adults and Teens in Europe

SAN JOSE, Calif. and AMSTERDAM, The Netherlands, June 25, 2018 (GLOBE NEWSWIRE) -- Align Technology, Inc. (Nasdaq:ALGN), today announced that it shipped its one millionth Invisalign case for the EMEA region in April, 2018.  This significant milestone for the company and the more than 34 thousand Invisalign-trained orthodontists and general dentists in the region reflects accelerating adoption of Invisalign clear aligner therapy in Europe, Middle East and Africa.

"I am immensely proud to announce that we have reached yet another significant milestone for EMEA with our one millionth Invisalign patient in the region. The demand and adoption rate for Invisalign clear aligners in EMEA has accelerated rapidly during recent years. I would like to thank our doctors for their trust and confidence in treating patients with the Invisalign system, and acknowledge the more than one million patients in EMEA who have chosen the most clinically advanced clear aligner system in the world to get a new, beautiful smile," said Simon Beard, Align Technology senior vice president and managing director, EMEA. Continued Beard, "In connection with this achievement, I'm pleased to share our plans to launch a pro bono campaign featuring Invisalign doctors across EMEA who will offer to treat patients with disabilities and help them improve their smiles."

The one millionth Invisalign patient in EMEA is 24-year old Julia Leibold from Freiburg, Germany who is in treatment with Dr. Ahmad Hagar, an Invisalign trained doctor practicing in Freiburg. Julia is being treated with the Invisalign Comprehensive Package, changing her aligners on a weekly basis, as per Dr Hagar's recommendation. In recognition of this major milestone for the company, Ms. Leibold will be featured in Align's new "One Millionth EMEA Invisalign Patient" campaign across the region, which includes PR, social and digital activities.  

"I wasn't surprised to hear that one million patients in EMEA had started treatment with Align Technology's clear aligners," said Dr. Hagar. "One great thing about this modern orthodontic method is that you use digital technology and can treat patients without using physical impressions. You start with a digital scan to produce the aligners that straighten the patient's teeth. This is much more comfortable for both the patient and the doctor. I am very satisfied with Julia's treatment process. She is a lovely young lady and she will have an even lovelier smile."

"When I found out that I was the one millionth patient in EMEA to start Invisalign treatment I was excited and totally speechless," said Julia Leibold, the one millionth Invisalign patient who works in sales. "I didn't choose traditional braces because I speak with so many people in my professional life and I didn't want them to see my braces. I would recommend Invisalign clear aligners to everyone because you can straighten your teeth with hardly anyone noticing."

In connection with this achievement, Align Technology will launch a pro bono campaign next month, where it will work with doctors across EMEA to offer Invisalign treatment to a number of patients with disabilities to help them get a new, straighter smile. In addition, between July 6 and July 8, 2018, Align will host Invisalign Digital Smile Awareness Days in cooperation with dental practices across Europe to drive the awareness of digital clear aligner therapy.

About Align Technology, Inc.

Align Technology designs and manufactures the Invisalign® system, the most advanced clear aligner system in the world, and iTero® intraoral scanners and services. Align's products help dental professionals achieve the clinical results they expect and deliver effective, cutting-edge dental options to their patients. Visit www.aligntech.com for more information.

For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit www.invisalign.com or www.invisalign.co.uk. For additional information about iTero digital scanning system, please visit www.itero.com.

Align Technology
Investors/Media
Madelyn Homick
(408) 470-1180
mhomick@aligntech.com

Media
Karina Ludz 
(+31) 621 143 420 
kludz@aligntech.com

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/de933255-444f-4646-b87f-38a11a0c5105

A video accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/af6c0ef4-3040-4f60-b913-dcf6df00948d




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Align Technology, Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Oboya participates in China International Import Expo1.11.2018 15:00Pressmeddelande

Newsletter Lerum, 1th November 2018 Oboya Horticulture Industries AB (publ) ("Oboya"), a global manufacturer and supplier of products and services for the cultivation industry, will participate in China International Import Expo in Shanghai, China. China International Import Expo (CIIE) is a six-day fair held from November 5 to November 10, 2018 at the National Convention & Exhibition Center in Shanghai, China. This fair brings together companies, exhibitors and professional buyers from all over the world. The fair creates new channels for companies from different countries and regions and provides the opportunity to do business, strengthen cooperation and promote trade. Oboya's strategy is to work globally in the various markets in the cultivation and flower industry, which it's important for Oboya to participate in the major trade shows. Oboya has its own booth at the fair and will show/marketing the European cultivation products and technology to the Chinese market. The purpose of t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum